Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 167
Filter
Add more filters

Publication year range
1.
Physiol Rev ; 97(3): 995-1043, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28539434

ABSTRACT

Estrogens have historically been associated with female reproduction, but work over the last two decades established that estrogens and their main nuclear receptors (ESR1 and ESR2) and G protein-coupled estrogen receptor (GPER) also regulate male reproductive and nonreproductive organs. 17ß-Estradiol (E2) is measureable in blood of men and males of other species, but in rete testis fluids, E2 reaches concentrations normally found only in females and in some species nanomolar concentrations of estrone sulfate are found in semen. Aromatase, which converts androgens to estrogens, is expressed in Leydig cells, seminiferous epithelium, and other male organs. Early studies showed E2 binding in numerous male tissues, and ESR1 and ESR2 each show unique distributions and actions in males. Exogenous estrogen treatment produced male reproductive pathologies in laboratory animals and men, especially during development, and studies with transgenic mice with compromised estrogen signaling demonstrated an E2 role in normal male physiology. Efferent ductules and epididymal functions are dependent on estrogen signaling through ESR1, whose loss impaired ion transport and water reabsorption, resulting in abnormal sperm. Loss of ESR1 or aromatase also produces effects on nonreproductive targets such as brain, adipose, skeletal muscle, bone, cardiovascular, and immune tissues. Expression of GPER is extensive in male tracts, suggesting a possible role for E2 signaling through this receptor in male reproduction. Recent evidence also indicates that membrane ESR1 has critical roles in male reproduction. Thus estrogens are important physiological regulators in males, and future studies may reveal additional roles for estrogen signaling in various target tissues.


Subject(s)
Estrogens/metabolism , Genitalia, Male/metabolism , Receptors, Estrogen/metabolism , Reproduction , Animals , Aromatase/genetics , Aromatase/metabolism , Genitalia, Male/pathology , Genitalia, Male/physiopathology , Genotype , Humans , Male , Mice, Knockout , Mutation , Phenotype , Prostate/metabolism , Prostate/pathology , Prostate/physiopathology , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Prostatic Diseases/physiopathology , Receptors, Estrogen/deficiency , Receptors, Estrogen/genetics , Signal Transduction
2.
Am J Physiol Renal Physiol ; 321(4): F466-F479, 2021 10 01.
Article in English | MEDLINE | ID: mdl-34423679

ABSTRACT

Intraurethral inoculation of mice with uropathogenic Escherichia coli (CP1) results in prostate inflammation, fibrosis, and urinary dysfunction, recapitulating some but not all of the pathognomonic clinical features associated with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). In both patients with LUTS and CP1-infected mice, we observed increased numbers and activation of mast cells and elevated levels of prostate fibrosis. Therapeutic inhibition of mast cells using a combination of a mast cell stabilizer, cromolyn sodium, and the histamine 1 receptor antagonist cetirizine di-hydrochloride in the mouse model resulted in reduced mast cell activation in the prostate and significant alleviation of urinary dysfunction. Treated mice showed reduced prostate fibrosis, less infiltration of immune cells, and decreased inflammation. In addition, as opposed to symptomatic CP1-infected mice, treated mice showed reduced myosin light chain-2 phosphorylation, a marker of prostate smooth muscle contraction. These results show that mast cells play a critical role in the pathophysiology of urinary dysfunction and may be an important therapeutic target for men with BPH/LUTS.NEW & NOTEWORTHY LUTS-associated benign prostatic hyperplasia is derived from a combination of immune activation, extracellular matrix remodeling, hyperplasia, and smooth muscle cell contraction in prostates of men. Using a mouse model, we describe the importance of mast cells in regulating these multiple facets involved in the pathophysiology of LUTS. Mast cell inhibition alleviates both pathology and urinary dysfunction in this model, suggesting the potential for mast cell inhibition as a therapeutic that prevents and reverses pathology and associated symptomology.


Subject(s)
Fibrosis/pathology , Mast Cells/physiology , Myocytes, Smooth Muscle/pathology , Prostatic Diseases/pathology , Animals , Anti-Allergic Agents/therapeutic use , Cetirizine/therapeutic use , Cromolyn Sodium/therapeutic use , Escherichia coli , Escherichia coli Infections/drug therapy , Escherichia coli Infections/metabolism , Escherichia coli Infections/pathology , Fibrosis/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Myocytes, Smooth Muscle/metabolism , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/metabolism , Urination
3.
Am J Physiol Renal Physiol ; 314(3): F407-F411, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29117997

ABSTRACT

Existing drugs that have been used in clinical practice for other purposes can prove useful for reutilization, since much of the safety profile and pharmacokinetics have been completed. Therefore, the drugs can enter clinical practice for a variety of causes with less regulatory burden. Metformin may prove to be such a drug; it may have a role in other diseases, besides the management of diabetes. In this perspective, we provide our findings and understanding of metformin as an alternative way to treat urological abnormal proliferation. We propose the potential mechanisms into two hallmarks: direct antiproliferative function via insulin-like growth factor (IGF) signaling pathway and epigenetic modulating via adjusting DNA methylation. These specific hallmarks may ultimately contribute to a better understanding of metformin in treating prostatic diseases.


Subject(s)
Cell Proliferation/drug effects , DNA Methylation/drug effects , Epigenesis, Genetic/drug effects , Metformin/pharmacology , Prostate/drug effects , Prostatic Diseases/drug therapy , Urological Agents/pharmacology , Animals , Humans , Male , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/genetics , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Signal Transduction/drug effects
4.
Cell Physiol Biochem ; 43(4): 1359-1368, 2017.
Article in English | MEDLINE | ID: mdl-28992620

ABSTRACT

BACKGROUND/AIMS: Cadmium (Cd) is an environmental pollutant with reproductive toxicity. Swertia mileensis is used in Chinese medicine for the treatment of prostatic deficits and named as Qing Ye Dan (QYD). This study was undertaken to investigate the potential protective effects of QYD against Cd-induced prostatic deficits. METHOD: Rat model of prostatic deficits was induced by 0.2 mg/kg/d CdCl2 subcutaneous injection for 15 days. The prostatic oxidative stress was evaluated by detecting the levels of malondialdehyde, nitric oxide, reduced/ oxidized glutathione, total sulfhydryl groups and enzymatic antioxidant status. The prostatic inflammation was estimated by testing the levels of pro-inflammatory cytokines. The levels of epithelial-mesenchymal transition (EMT) markers E-cadherin, fibronectin, vimentin and α-smooth muscle actin were measured by qPCR analysis. Additionally, the prostatic expressions of transforming growth factor-ß1 (TGF-ß1), type I TGF-ß receptor (TGF-ßRI), Smad2, phosphorylation-Smad2 (p-Smad2), Smad3, p-Smad3, Smad7, nuclear related factor-2 (Nrf-2), heme oxygenase-1 (HO-1), B-cell CLL/lymphoma (Bcl)-2 and Bcl-2-associated X protein (Bax) were measured by western blot assay. RESULTS: It was found that QYD ameliorated the Cd-induced prostatic oxidative stress and inflammation, attenuated prostatic EMT, inhibited the TGF-ß1/Smad pathway, increased Bcl-2/Bax ratio and enhanced the activity of Nrf-2/HO-1 pathway. CONCLUSION: These results showed that QYD could ameliorate Cd-induced prostatic deficits via modulating Nrf-2/HO-1 and TGF-ß1/Smad pathways.


Subject(s)
Cadmium/adverse effects , Drugs, Chinese Herbal/therapeutic use , Oxidative Stress/drug effects , Prostate/drug effects , Prostatic Diseases/chemically induced , Prostatic Diseases/drug therapy , Signal Transduction/drug effects , Animals , Epithelial-Mesenchymal Transition/drug effects , Heme Oxygenase-1/metabolism , Male , NF-E2-Related Factor 2/metabolism , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Rats , Rats, Wistar , Smad Proteins/metabolism , Transforming Growth Factor beta1/metabolism
5.
J Sci Food Agric ; 97(13): 4451-4458, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28276068

ABSTRACT

BACKGROUND: Obesity is associated with increased risk of a number of serious medical conditions, including urological disorders. This study investigated the effect of lipidic extracts of saladette tomato pomace (STP) and Serenoa repens (SR) on the prostate and bladder in a rat obese model induced by high-carbohydrate diet. RESULTS: High-sucrose-fed rats showed higher prostate weight as well as increased contractility and stromal and epithelial hyperplasia in the prostate. Treatment with STP and SR improved contractility and diminished hyperplasia and hypertrophy in the prostate. Obese animals also showed impaired bladder contractility, but neither extract reversed this deterioration. In the histological study, a disarray in the process of smooth muscle cell proliferation with non-parallel fibers was observed; interestingly, treatment with STP and SR led to improvement in this derangement. CONCLUSION: These findings indicated impaired contractility and hyperplasia in the prostate and bladder of obese rats induced by high sucrose. STP and SR could enhance prostate function by reducing contractility and hyperplasia and improve smooth muscle fiber structure and decrease cell proliferation in the bladder, suggesting their possible health-beneficial effects on lower urinary tract symptoms. © 2017 Society of Chemical Industry.


Subject(s)
Obesity/complications , Plant Extracts/administration & dosage , Prostate/drug effects , Serenoa/chemistry , Solanum lycopersicum/chemistry , Urinary Bladder/drug effects , Animals , Humans , Male , Obesity/metabolism , Prostate/physiopathology , Prostatic Diseases/drug therapy , Prostatic Diseases/etiology , Prostatic Diseases/metabolism , Prostatic Diseases/physiopathology , Rats , Rats, Wistar , Urinary Bladder/physiopathology , Urinary Bladder Diseases/drug therapy , Urinary Bladder Diseases/etiology , Urinary Bladder Diseases/metabolism , Urinary Bladder Diseases/physiopathology
6.
Future Oncol ; 11(23): 3197-206, 2015.
Article in English | MEDLINE | ID: mdl-26551285

ABSTRACT

A fully differentiated epithelium of the normal prostate gland allows epithelial cells to de-differentiate into mesenchymal-like derivatives via the process of epithelial-mesenchymal transition (EMT) and redifferentiate via the reverse process, mesenchymal-epithelial transition. This review discusses the phenotypic changes associated with EMT and its programming in the development of the two growth disorders of the aging prostate gland, benign prostatic hyperplasia and prostate adenocarcinoma. Considering the cellular heterogeneity that characterizes both conditions, identifying the transcriptional programming of the phenotypic framework defining EMT and its reverse process mesenchymal-epithelial transition in their pathological landscape will enable novel platforms for biomarker-driven therapeutics and their implementation in benign prostatic hyperplasia and prostate cancer.


Subject(s)
Epithelial-Mesenchymal Transition , Prostatic Diseases/pathology , Animals , Cellular Microenvironment/genetics , Epigenesis, Genetic , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation , Humans , Male , Phenotype , Prostatic Diseases/etiology , Prostatic Diseases/metabolism , Prostatic Hyperplasia/etiology , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/etiology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Signal Transduction , Sumoylation
7.
Clin Nephrol ; 84(6): 339-42, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26396096

ABSTRACT

Alkaptonuria is a genetic disorder characterized by an accumulation of homogentisic acid due to an enzymatic defect of homogentisate 1,2 dioxygenase. The homogentisic acid is excreted exclusively by both glomerular filtration and tubular secretion leading to the renal parenchyma being exposed to high concentrations of homogentisic acid. The alkaptonuric patients are at higher risk of renal stones (and of prostate stones for males), usually in the later stages of the disease. We describe the case of a 51-year-old man whose renal and prostate stones were analyzed by X-ray diffraction and infrared spectroscopy, respectively. We review the cases of alkaptonuria (AKU) patients reported in the literature for whom the composition of kidney or prostate stones was assessed with physical or chemical techniques. In this paper, we also discuss the advantages and drawbacks of the different methodologies.


Subject(s)
Alkaptonuria/complications , Calculi/chemistry , Kidney Calculi/chemistry , Prostatic Diseases/metabolism , Alkaptonuria/urine , Apatites/analysis , Calcium Oxalate/analysis , Calcium Phosphates/analysis , Calculi/etiology , Homogentisic Acid/urine , Humans , Kidney Calculi/etiology , Male , Middle Aged , Prostatic Diseases/etiology , Spectrophotometry, Infrared , X-Ray Diffraction
8.
Curr Urol Rep ; 16(8): 51, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26077355

ABSTRACT

The physiology of testosterone production and action are closely related to prostatic disease. An understanding of the natural history of testosterone and prostate growth and development is needed in order to understand this complex relationship. Lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), prostate cancer, and sexual function are common disorders for which testosterone is thought to play a role. Proposed in this review are some theories as to how testosterone interacts to potentially ameliorate these conditions. Further research is needed, but we feel our proposed points are valid given the review of the literature.


Subject(s)
Hormone Replacement Therapy , Prostatic Diseases/drug therapy , Testosterone/metabolism , Humans , Male , Metabolic Syndrome/complications , Metabolic Syndrome/metabolism , Obesity/complications , Obesity/metabolism , Prostate/metabolism , Prostatic Diseases/etiology , Prostatic Diseases/metabolism
9.
Histochem Cell Biol ; 142(3): 269-84, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24562790

ABSTRACT

Senescence is associated with hormonal imbalance and prostatic disorders. Angiogenesis is fundamental for the progression of malignant lesions and is a promising target for prostate cancer treatment. The aim was to characterize matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses in the prostate during senescence and following antiangiogenic and/or androgen ablation therapies, comparing them to cancer progression features in TRAMP mice. Aged male mice (52-week-old FVB) were submitted to antiangiogenic treatments with SU5416 (6 mg/kg; i.p.) and/or TNP-470 (15 mg/kg; s.c). Finasteride (20 mg/kg; s.c.) was administered alone or associated to both inhibitors. Dorsolateral prostate was collected for light microscopy, and immunohistochemistry and Western blotting collected for MMP-9 and IGFR-1. Senescence led to inflammation and different proliferative lesions in the prostate, as well as to increased MMP-9 and IGFR-1, resembling TRAMP mice prostatic microenvironment. Antiangiogenic therapies promoted recovery and/or interruption of age-associated alterations, presenting differential effects on the molecules studied. SU5416 acted mainly on MMP-9, whereas TNP-470 showed its best influence on IGFR-1 levels. Finasteride administration, alone or in combination with antiangiogenic agents, also resulted in regression of inflammation and neoplastic lesions, besides having a negative modulatory effect on both MMP-9 and IGFR-1. We concluded that stimulated tissue remodeling and proliferative processes during senescence predisposed the prostate to malignant disorders. The combination of different agents was more effective to minimize prostatic imbalance during this period, probably due to the differential action of each drug on factors involved in cell proliferation and extracellular matrix remodeling, resulting in a broader spectrum of effects following the combined treatment.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Matrix Metalloproteinase 9/metabolism , Prostatic Diseases/drug therapy , Prostatic Diseases/metabolism , Receptor, IGF Type 1/metabolism , Age Factors , Angiogenesis Inhibitors/administration & dosage , Animals , Male , Matrix Metalloproteinase 9/analysis , Mice , Mice, Inbred Strains , Mice, Transgenic , Prostatic Diseases/pathology , Receptor, IGF Type 1/analysis
10.
Mol Cell Endocrinol ; 588: 112223, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38556160

ABSTRACT

Maternal malnutrition can alter developmental biology, programming health and disease in offspring. The increase in sugar consumption during the peripubertal period, a worldwide concern, also affects health through adulthood. Studies have shown that maternal exposure to a low protein diet (LPD) is associated with an increase in prostate disease with aging. However, the combined effects of maternal LPD and early postnatal sugar consumption on offspring prostate disorders were not investigated. The effects on aging were evaluated using a maternal gestational model with lactational LPD (6% protein) and sugar consumption (10%) from postnatal day (PND) 21-90, associating the consequences on ventral prostate (VP) rats morphophysiology on PND540. An increase was shown in mast cells and in the VP of the CTR + SUG and Gestational and Lactational Low Protein (GLLP) groups. In GLLP + SUG, a significant increase was shown in TGF-ß1 expression in both the systemic and intra-prostatic forms, and SMAD2/3p had increased. The study identified maternal LPD and sugar consumption as risk factors for prostatic homeostasis in senility, activating the TGFß1-SMAD2/3 pathway, a signaling pathway with potential markers for prostatic disorders.


Subject(s)
Malnutrition , Maternal Nutritional Physiological Phenomena , Prenatal Exposure Delayed Effects , Prostate , Prostatic Diseases , Animals , Male , Female , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Prostatic Diseases/pathology , Prostatic Diseases/etiology , Prostatic Diseases/metabolism , Malnutrition/complications , Prostate/metabolism , Prostate/pathology , Rats , Inflammation/pathology , Inflammation/metabolism , Transforming Growth Factor beta1/metabolism , Transforming Growth Factor beta1/genetics , Diet, Protein-Restricted/adverse effects , Smad2 Protein/metabolism , Rats, Wistar , Smad3 Protein/metabolism , Smad3 Protein/genetics , Signal Transduction , Animals, Newborn , Mast Cells/metabolism
11.
Int Braz J Urol ; 39(3): 393-401, 2013.
Article in English | MEDLINE | ID: mdl-23849571

ABSTRACT

INTRODUCTION: Published data suggest that patients with acromegaly have an increased prevalence of prostate disorders. OBJECTIVE: To evaluate prostatic disorders in acromegalic patients comparing these results after one year of treatment of acromegaly and with a group of healthy men. MATERIALS AND METHODS: This study was composed of two parts: sectional study comparing patients with healthy controls (baseline) and prospective, longitudinal study (at baseline and after one year of treatment). Forty acromegalic patients were enrolled and evaluated at baseline and after one year with the application of international prostatic symptoms score (IPSS), digital rectal examination, measurements of growth hormone (GH), insulin-like growth factor-I (IGF-I), insulin-like growth factor-binding protein-3 (IGFBP-3), sex hormone-binding globulin (SHBG), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, total and free prostate-specific antigen (PSA) levels and prostate ultrasonography (US). Thirty healthy men were selected as control group. RESULTS: We stratified patients and controls according to age, considering 40 years-old as cut off. Healthy controls under 40 had IPSS values lower than acromegalic patients. When considering only older patients and controls prostate hyperplasia and structural abnormalities were more frequent in acromegalics. After one year of treatment there was significant decrease in GH, IGF-I and prostate volume in acromegalics over 40 years-old. CONCLUSIONS: Acromegalics under 40 have more urinary symptoms according to IPSS and above 40 years-old higher frequency of structural changes and increased prostate volume than healthy men. Significant reduction of GH and IGF-I levels during treatment of acromegaly leads to decrease in the prostate volume.


Subject(s)
Acromegaly/physiopathology , Acromegaly/therapy , Prostatic Diseases/physiopathology , Acromegaly/metabolism , Adult , Age Factors , Aged , Brazil , Case-Control Studies , Digital Rectal Examination , Gonadotropins, Pituitary/blood , Growth Hormone/blood , Humans , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor I/analysis , Male , Middle Aged , Prostate-Specific Antigen/blood , Prostatic Diseases/metabolism , Sex Hormone-Binding Globulin/analysis , Testosterone/blood , Treatment Outcome
12.
J Proteome Res ; 11(4): 2386-96, 2012 Apr 06.
Article in English | MEDLINE | ID: mdl-22339264

ABSTRACT

Urinary expressed prostatic secretion or "EPS-urine" is proximal tissue fluid that is collected after a digital rectal exam (DRE). EPS-urine is a rich source of prostate-derived proteins that can be used for biomarker discovery for prostate cancer (PCa) and other prostatic diseases. We previously conducted a comprehensive proteome analysis of direct expressed prostatic secretions (EPS). In the current study, we defined the proteome of EPS-urine employing Multidimensional Protein Identification Technology (MudPIT) and providing a comprehensive catalogue of this body fluid for future biomarker studies. We identified 1022 unique proteins in a heterogeneous cohort of 11 EPS-urines derived from biopsy negative noncancer diagnoses with some benign prostatic diseases (BPH) and low-grade PCa, representative of secreted prostate and immune system-derived proteins in a urine background. We further applied MudPIT-based proteomics to generate and compare the differential proteome from a subset of pooled urines (pre-DRE) and EPS-urines (post-DRE) from noncancer and PCa patients. The direct proteomic comparison of these highly controlled patient sample pools enabled us to define a list of prostate-enriched proteins detectable in EPS-urine and distinguishable from a complex urine protein background. A combinatorial analysis of both proteomics data sets and systematic integration with publicly available proteomics data of related body fluids, human tissue transcriptomic data, and immunohistochemistry images from the Human Protein Atlas database allowed us to demarcate a robust panel of 49 prostate-derived proteins in EPS-urine. Finally, we validated the expression of seven of these proteins using Western blotting, supporting the likelihood that they originate from the prostate. The definition of these prostatic proteins in EPS-urine samples provides a reference for future investigations for prostatic-disease biomarker studies.


Subject(s)
Prostate/chemistry , Prostatic Secretory Proteins/urine , Proteome/analysis , Proteomics/methods , Case-Control Studies , Chromatography, High Pressure Liquid , Databases, Protein , Gene Expression Profiling , Humans , Male , Mass Spectrometry , Prostate/metabolism , Prostatic Diseases/metabolism , Prostatic Diseases/urine , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/urine , Prostatic Secretory Proteins/chemistry , Prostatic Secretory Proteins/metabolism , Proteome/metabolism , Reproducibility of Results
13.
Proc Natl Acad Sci U S A ; 106(9): 3443-8, 2009 Mar 03.
Article in English | MEDLINE | ID: mdl-19202053

ABSTRACT

Corpora amylacea (CA) are a frequent microscopic finding in radical prostatectomy specimens from men undergoing treatment for prostate cancer. Although often observed histologically to be associated with inflammation, the contribution of CA to prostatitis-related symptoms of unknown etiology or to prostate carcinogenesis remains unclear. Prostatic calculi (PC), which potentially represent calcified forms of CA, are less common but can cause urological disease including urinary retention and prostatitis. We conducted a comprehensive compositional analysis of CA/PC to gain insight into their biogenesis. Infrared spectroscopy analysis of calculi collected from 23 patients confirmed a prevalence of calcium phosphate in the form of hydroxyapatite. This result sets PC apart from most urinary stones, which largely are composed of calcium oxalate. Tandem mass spectrometry-based proteomic analysis of CA/PC revealed that lactoferrin is the predominant protein component, a result that was confirmed by Western blot analysis. Other proteins identified, including calprotectin, myeloperoxidase, and alpha-defensins, are proteins contained in neutrophil granules. Immunohistochemistry (IHC) suggested the source of lactoferrin to be prostate-infiltrating neutrophils as well as inflamed prostate epithelium; however, IHC for calprotectin suggested prostate-infiltrating neutrophils as a major source of the protein, because it was absent from other prostate compartments. This study represents a definitive analysis of the protein composition of prostatic CA and calculi and suggests that acute inflammation has a role in their biogenesis--an intriguing finding, given the prevalence of CA in prostatectomy specimens and the hypothesized role for inflammation in prostate carcinogenesis.


Subject(s)
Acute-Phase Proteins/metabolism , Prostatic Diseases/complications , Prostatic Diseases/metabolism , Prostatic Neoplasms/complications , Prostatic Neoplasms/metabolism , Acute-Phase Proteins/chemistry , Calcium Phosphates/metabolism , Durapatite/metabolism , Humans , Inflammation/metabolism , Lactoferrin/metabolism , Male , Prostatic Diseases/pathology , Prostatic Neoplasms/pathology , Tandem Mass Spectrometry
14.
Przegl Lek ; 69(12): 1297-301, 2012.
Article in Polish | MEDLINE | ID: mdl-23750443

ABSTRACT

The disturbed balance between production of reactive oxygen and nitrogen species (RONS) and efficiency of antioxydative systems leads to oxidative stress. This may be the cause of permanent biomolecules' damage. The results of many researches show dependence between disturbance in oxidative balance. And oxidative damage in prostate cells. However no clear evidence have been found that oxidative stress may lead to development of prostate cancer.


Subject(s)
Oxidative Stress , Prostatic Diseases/metabolism , Humans , Male , Prostatic Neoplasms/metabolism , Reactive Nitrogen Species/metabolism , Reactive Oxygen Species/metabolism
15.
BJU Int ; 107(8): 1210-5, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20942832

ABSTRACT

UNLABELLED: Study Type--Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? The anatomy of the periprostatic tissues, in particular the fascial layers and neurovascular structures, remain a somewhat enigmatic and controversial area. Despite the considerable advances made in this area since the original dissections of Walsh and Donker almost thirty years ago, the precise location and function of these structures remains uncertain. The topic is of tremendous importance as we continue to refine surgical techniques to allow men the maximum opportunity to recover erectile function following radical prostatectomy. Yet many of these surgical refinements are not based on definitive knowledge of the relevant anatomy and clearly more knowledge is required. For the first time, we have not just characterized the quantitative nature of the periprostatic nerves, but we also offer some insight into the likely functional nature of these nerves by selectively staining the sympathetic and parasympathetic nerves using immunohistochemical methods. OBJECTIVE: • To characterize the immunohistochemical nature of sympathetic and parasympathetic nerves surrounding the prostate. MATERIALS AND METHODS: • Using serial sectioning, four male cadavers were investigated using a combination of haematoxylin and eosin staining and immunohistochemistry. Both the sympathetic and parasympathetic contributions to the autonomic nervous system in the periprostatic region were assessed by staining analysis, the number of nerves fibres was quantified, their position relative to the prostate recorded and their function inferred. • The fascial architecture of the neurovascular bundle (NVB) was also quantified. RESULTS: • Approximately 27.8% of all nerve fibres identified were found on the anterior half of the prostate, above the 3 to 9 o'clock level. At the base, mid, and apex of prostate, parasympathetic fibres accounted for 4%, 5% and 6.8% of the nerves located on the anterolateral aspect of the prostate, respectively. • Sympathetic nerves found above the 3 to 9 o'clock level represented ≈15% of the total number of nerves. • When staining the periprostatic fascia, the classical NVB exhibited a distinct fascial architecture with three separate compartments. CONCLUSIONS: • A tiny minority of nerves in the anterior periprostatic region are functionally significant parasympathetic nerves. • There is little anatomical evidence to support higher incisions in the lateral prostatic fascia to spare cavernous nerve fibres, although such approaches may reduce the risk of traction injury on the more posterolaterally located NVB. • The presence of distinct fascial compartments in the NVB is also confirmed.


Subject(s)
Autonomic Nervous System/metabolism , Nerve Tissue/metabolism , Penis/innervation , Prostate/innervation , Prostatic Diseases/metabolism , Cadaver , Humans , Immunohistochemistry , Male , Prostate/surgery , Prostatectomy/methods , Prostatic Diseases/pathology , Prostatic Diseases/surgery
16.
Urol Res ; 39(3): 165-70, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20967440

ABSTRACT

Awareness of the chemical composition of prostatic calculi is of great importance for pathogenesis of prostatic lithiasis, the feasibility of FTIR microspectroscopic mapping system used for rapidly screening and detecting the real composited components of prostatic calculi in a short time was initially evaluated. Prostatic calculi were retrieved during transurethral resection of the prostate from nine patients diagnosed having benign prostatic hyperplasia with lower urinary tract symptoms. The level of serum prostatic-specific antigen was within 0-12.63 ng/ml. The calculi samples were examined and compared using FTIR microspectroscopic mapping system, or the traditional FTIR and Raman microspectroscopies. The traditional FTIR microspectroscopic results indicate that nine calculi samples mainly consisted of carbonated HA (hydroxyapatite), but calcium oxalate (undifferentiated) might be also detected in some samples. However, Raman spectral results could detect three components, HA, COM (calcium oxalate monohydrate) or COD (calcium oxalate dihydrate) separated in nine samples. Different compositions in the prostatic calculi were obtained by both spectroscopic detections with manual single-point random analysis implying that both manually traditional methods were failed to provide the real chemical composition of the prostatic calculi in a short time. The FTIR microscopic mapping system via point-by-point mapping analysis evidenced that it could rapidly detect all the complicated components distributed within the prostatic calculi rather than uncertain components detected by traditional FTIR or Raman microspectroscopy. More studies should be carried out in future. This preliminary result suggests that the FTIR mapping better characterizes the stone composition over single-point FTIR and Raman microscopic analysis in prostatic calculi.


Subject(s)
Calculi/chemistry , Calculi/metabolism , Prostatic Diseases/diagnosis , Prostatic Diseases/metabolism , Spectroscopy, Fourier Transform Infrared/methods , Aged , Aged, 80 and over , Calcium Oxalate/analysis , Calcium Oxalate/metabolism , Durapatite/analysis , Durapatite/metabolism , Feasibility Studies , Humans , Male , Mass Screening , Middle Aged , Spectrum Analysis, Raman/methods
17.
Sci Rep ; 11(1): 22208, 2021 11 15.
Article in English | MEDLINE | ID: mdl-34782677

ABSTRACT

Supraphysiologic androgen (SPA) inhibits cell proliferation in prostate cancer (PCa) cells by transcriptional repression of DNA replication and cell-cycle genes. In this study, quantitative glycoprotein profiling identified androgen-regulated glycoprotein networks associated with SPA-mediated inhibition of PCa cell proliferation, and androgen-regulated glycoproteins in clinical prostate tissues. SPA-regulated glycoprotein networks were enriched for translation factors and ribosomal proteins, proteins that are known to be O-GlcNAcylated in response to various cellular stresses. Thus, androgen-regulated glycoproteins are likely to be targeted for O-GlcNAcylation. Comparative analysis of glycosylated proteins in PCa cells and clinical prostate tissue identified androgen-regulated glycoproteins that are differentially expressed prostate tissues at various stages of cancer. Notably, the enzyme ectonucleoside triphosphate diphosphohydrolase 5 was found to be an androgen-regulated glycoprotein in PCa cells, with higher expression in cancerous versus non-cancerous prostate tissue. Our glycoproteomics study provides an experimental framework for characterizing androgen-regulated proteins and glycoprotein networks, toward better understanding how this subproteome leads to physiologic and supraphysiologic proliferation responses in PCa cells, and their potential use as druggable biomarkers of dysregulated AR-dependent signaling in PCa cells.


Subject(s)
Androgens/metabolism , Glycoproteins/metabolism , Prostatic Diseases/metabolism , Prostatic Neoplasms/metabolism , Proteome , Proteomics , Biomarkers , Cell Line, Tumor , Computational Biology/methods , Gene Expression Regulation, Neoplastic , Glycoproteins/genetics , Humans , Male , Mass Spectrometry , Prostatic Diseases/etiology , Prostatic Neoplasms/etiology , Proteomics/methods , Signal Transduction
18.
Nat Rev Urol ; 18(10): 597-610, 2021 10.
Article in English | MEDLINE | ID: mdl-34294916

ABSTRACT

Senescent cells accumulate with age in all tissues. Although senescent cells undergo cell-cycle arrest, these cells remain metabolically active and their secretome - known as the senescence-associated secretory phenotype - is responsible for a systemic pro-inflammatory state, which contributes to an inflammatory microenvironment. Senescent cells can be found in the ageing prostate and the senescence-associated secretory phenotype and can be linked to BPH and prostate cancer. Indeed, a number of signalling pathways provide biological plausibility for the role of senescence in both BPH and prostate cancer, although proving causality is difficult. The theory of senescence as a mechanism for prostate disease has a number of clinical implications and could offer opportunities for targeting in the future.


Subject(s)
Aging/physiology , Cellular Senescence/physiology , Prostate/physiology , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/pathology , Senescence-Associated Secretory Phenotype/physiology , Aging/immunology , Cellular Microenvironment/immunology , Cellular Senescence/immunology , Cytokines/immunology , Cytokines/metabolism , Humans , Inflammation/immunology , Inflammation/metabolism , Male , Prostate/cytology , Prostate/immunology , Prostatic Diseases/immunology , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Prostatic Hyperplasia/immunology , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/immunology , Prostatic Neoplasms/metabolism , Senescence-Associated Secretory Phenotype/immunology , Tumor Microenvironment/immunology
19.
PLoS One ; 16(3): e0247930, 2021.
Article in English | MEDLINE | ID: mdl-33760831

ABSTRACT

Prostate cancer (PCa) is the most common cancer and the third most frequent cause of male cancer death in Germany. MicroRNAs (miRNA) appear to be involved in the development and progression of PCa. A diagnostic differentiation from benign prostate hyperplasia (BPH) is often only possible through transrectal punch biopsy. This procedure is described as painful and carries risks. It was investigated whether urinary miRNAs can be used as biomarkers to differentiate the prostate diseases above. Therefore urine samples from urological patients with BPH (25) or PCa (28) were analysed using Next-Generation Sequencing to detect the expression profile of total and exosomal miRNA/piRNA. 79 miRNAs and 5 piwi-interacting RNAs (piRNAs) were significantly differentially expressed (adjusted p-value < 0.05 and log2-Fc > 1 or < -1). Of these, 6 miRNAs and 2 piRNAs could be statistically validated (AUC on test cohort > = 0.7). In addition, machine-learning algorithms were used to identify a panel of 22 additional miRNAs, whose interaction makes it possible to differentiate the groups as well. There are promising individual candidates for potential use as biomarkers in prostate cancer. The innovative approach of applying machine learning methods to this kind of data could lead to further small RNAs coming into scientific focus, which have so far been neglected.


Subject(s)
MicroRNAs/metabolism , Prostate/metabolism , Prostatic Diseases/diagnosis , Prostatic Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biopsy , Diagnosis, Differential , High-Throughput Nucleotide Sequencing , Humans , Male , MicroRNAs/genetics , Middle Aged , Prostate/pathology , Prostatic Diseases/genetics , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology
20.
J Ethnopharmacol ; 267: 113498, 2021 Mar 01.
Article in English | MEDLINE | ID: mdl-33091496

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Hyperplasia, Tumors and cancers are various forms of proliferative disorders affecting humans. Surgery is the main treatment approach while other options are also associated with adverse effects. There is therefore a need for the development of better alternative therapy that is cost effective and readily available with little or no adverse effect. Some bioactive agents in medicinal plants exhibit their anti-proliferative potential by induction of mitochondrial permeability transition pore (mPT) opening. Gloriosa superba, a medicinal plant, is folklorically used in the treatment of tumors and cancers. AIM OF THE STUDY: This study therefore aimed at investigating the effect of ethanol leaf extract of Gloriosa superba (EEGS) on mPT and monosodium glutamate-induced proliferative disorder in some specific tissues using rat model. MATERIALS AND METHODS: Isolated rat liver mitochondria were exposed to different concentrations (10, 30, 50, 70 and 90 µg/ml) of EEGS. The mPT pore opening, cytochrome c release, mitochondrial ATPase activity and lipid peroxidation were assessed spectrophotometrically. Caspases 9 and 3 activities were carried out using ELISA technique. Histological assessment of the liver, prostate and uterus of normal and monosodium glutamate (MSG)-treated rats were carried out. RESULTS: The results showed significant induction of mPT pore opening, release of cytochrome c, enhancement of mitochondrial ATPase activity, inhibition of lipid peroxidation and activation of caspases 9 and 3 activities by EEGS. The histological assessment revealed the presence of MSG-induced hepato-cellular damage, benign prostate hyperplasia and uterine hyperplasia which were ameliorated by EEGS co-administration. CONCLUSIONS: These findings suggest that EEGS contains putative agents that can induce apoptosis via induction of mPT pore opening and as well protect against MSG-induced hepato-cellular damage and proliferative disorder in prostate and uterus.


Subject(s)
Cell Proliferation/drug effects , Chemical and Drug Induced Liver Injury/prevention & control , Colchicaceae , Liver/drug effects , Membrane Potential, Mitochondrial/drug effects , Mitochondria, Liver/drug effects , Plant Extracts/pharmacology , Prostate/drug effects , Prostatic Diseases/prevention & control , Uterine Diseases/prevention & control , Uterus/drug effects , Animals , Apoptosis/drug effects , Apoptosis Regulatory Proteins/metabolism , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/pathology , Colchicaceae/chemistry , Disease Models, Animal , Female , Hyperplasia , Lipid Peroxidation/drug effects , Liver/metabolism , Liver/pathology , Male , Mitochondria, Liver/metabolism , Mitochondria, Liver/pathology , Plant Extracts/isolation & purification , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/chemically induced , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Rats, Wistar , Signal Transduction , Sodium Glutamate , Uterine Diseases/chemically induced , Uterine Diseases/metabolism , Uterine Diseases/pathology , Uterus/metabolism , Uterus/pathology
SELECTION OF CITATIONS
SEARCH DETAIL